ChinaBio Today -- GlaxoSmithKline will begin manufacturing its treatment for flu, Relenza, in China to supply China’s domestic market. GSK received approval of the drug in September from the SFDA. Relenza, like Tamiflu from Roche, aims at reducing both the severity and the duration of flu symptoms, though some resistance to the drugs seems to be evident. More details...
